Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Literature
1.
2.
Zhang J, Tu Y, Lu Y et al (2008) Protein Z-dependent protease inhibitor deficiency produces a more severe murine phenotype than protein Z deficiency. Blood 111:4973–4978CrossRefPubMedPubMedCentral
3.
Sofi F, Cesari F, Abbat R et al (2010) A meta-analysis of potential risks of low levels of protein Z for diseases related to vascular thrombosis. Thromb Haemost 103:749–756CrossRefPubMedPubMedCentral
4.
Pardos-Gea J, Ordi-Ros J, Serrano S et al (2008) Protein Z levels and anti-protein Z antibodies in patients with arterial and venous thrombosis. Thromb Res 121:727–734CrossRefPubMed
5.
Sofi F, Cesari F, Pratesi G et al (2007) Low protein Z levels in patients with peripheral arterial disease. Thromb Haemost 89:1114–1117
6.
7.
D’Agostino RB, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117:743–753CrossRefPubMed
8.
9.
Vasse M, Denoyelle C, Corbière C et al (2006) Human endothelial cells synthesize protein Z, but not the protein Z dependent inhibitor. Thromb Haemost 95(2006):519–523PubMed
10.
Sofi F, Cesari F, Vigiani S et al (2005) Protein Z levels in different phases of activity of coronary atherosclerosis. J Thromb Haemost 3:2254–2258CrossRefPubMed
Metadata
Title
Protein Z and atherosclerotic disease: a less close relationship than though
Author
José Pardos-Gea
Publication date
01-04-2017
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2017
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-016-1457-x

Other articles of this Issue 3/2017

Journal of Thrombosis and Thrombolysis 3/2017 Go to the issue

Letter to the Editor

Acute apixaban treatment of heparin-induced thrombocytopenia

ReviewPaper

Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs)

OriginalPaper

The scope and value of an anticoagulation stewardship program at a community teaching hospital

Letter to the Editor

ST-elevation no myocardial infarction

OriginalPaper

Use of an extended INR follow-up interval for Veteran patients in an anticoagulation clinic

Report

Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits